Medytox’s American dream falters with returned botox rights
By Kim, Jin-Gu | translator Alice Kang
21.09.08 17:30:52
가나다라
0
Rights to a new botulinum toxin substance that was exported to Allergan (now Abbvie) through a technology transfer contract was returned to Medytox.
Received Phase 3 clinical trail data from ABBvie…is internally reviewing whether to enter the U.S. business
Medytox’s plans to overcome the license revocation in Korea by entering the US market, have come to a halt with AbbVie, which had been conducting global trials for the new botulinum toxin candidate 'MT10109L,’ returning its rights to Medytox.
◆A technology export agreement worth up to ₩400 billion was returned in 8 years
On the 8th, Medytox announced that AbbVie has returned the rights concerning MT10109L, an improved botulinum toxin candidate, to its company. The right was returned in 8 years since the technology export.
Medytox had signed a licensing-out agreement for its botulinum toxin candidate in 2013 to Allergan (now AbbVie) and handed over th
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)